Physician profile
Robert J Bisbee
NPI 1750384806
$728.60
in general payments reported to CMS, 2019-2025
15 companies · $343 in 2025
The $343 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $50.67 · 2024: $335 · 2025: $343.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $729.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $728.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Travere Therapeutics, INC. | $265.96 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $87.03 | 2025 | Dupixent |
| Mallinckrodt Hospital Products INC. | $59.75 | 2024-2025 | Acthar, Terlivaz |
| Abbvie INC. | $50.67 | 2023 | |
| Melinta Therapeutics, LLC | $36.16 | 2025 | Rezzayo |
| Inogen, INC. | $33.27 | 2025 | |
| Soleno Therapeutics, INC. | $33.08 | 2025 | Vykat Xr |
| Janssen Biotech, INC. | $31.75 | 2025 | Tremfya, Simponi, Stelara |
| Astrazeneca Pharmaceuticals LP | $31.69 | 2024 | Airsupra, Fasenra |
| Takeda Pharmaceuticals U.S.A., INC. | $23.08 | 2025 | Gattex |
| Merck Sharp & Dohme LLC | $16.94 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.71 | 2025 | Jascayd |
| Lilly USA, LLC | $14.88 | 2025 | |
| Phathom Pharmaceuticals, INC. | $14.01 | 2025 | Voquezna |
| Abbott Laboratories | $13.62 | 2024 | Freestyle Libre 3 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Bisbee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.